#Canada #Hamilton #radiopharmaceuticals #CPDC #Cadena Research

CPDC Launches Cadena Research to Advance Radiopharmaceutical Development

HAMILTON, ON, Sept. 29, 2025 – In an exciting announcement, the Centre for Probe Development and Commercialization (CPDC), recognized globally for its expertise in radiopharmaceuticals, has introduced Cadena Research, a new preclinical contract research organization (CRO). This innovative endeavor aims to fill a critical void in the fast-growing radiopharmaceutical sector by offering specialized support for early-phase drug development.

Cadena Research is designed to provide comprehensive services covering the entire spectrum of preclinical development. Its offerings include in vitro and in vivo research, toxicology assessments, lead optimization, imaging capabilities, and advanced radiochemistry. Furthermore, the organization is equipped with GLP (Good Laboratory Practice) capabilities for Investigational New Drug (IND)-enabling studies, ensuring rigorous compliance with industry standards.

Empowering Innovations with Tailored Solutions

What sets Cadena Research apart is its commitment to empowering innovators in the radiopharmaceutical industry. The organization understands the complexities of moving from scientific discovery to the clinical setting, and its team of seasoned professionals provides strategic advisory services that cater to the unique needs of each client. Every project benefits from dedicated project management, ensuring effective communication and timely execution from start to finish.

Martin Poirier, the Vice President of Contract Research at Cadena Research, emphasizes the organization’s mission: “Our goal is to empower the next generation of breakthroughs in radiopharmaceuticals. The success of our clients is our top priority,” he stated. Poirier, who brings 25 years of CRO operational experience to the table, believes that personalized support and expert guidance are crucial for facilitating efficient transitions from discovery to clinical phases.

A Strategic Response to Growing Industry Needs

As the radiopharmaceutical industry faces unprecedented growth, the demand for specialized and agile preclinical support has increased significantly. Owen Roberts, CEO of CPDC, noted that “The launch of Cadena Research builds upon our proven track record of creating successful global ventures. We are confident that this new venture will assist researchers in efficiently moving their innovations from concept to clinic.” Cadena Research is poised to follow in the footsteps of successful CPDC ventures, providing the necessary foundation for researchers to navigate the complexities of drug development.

About Cadena Research

Cadena Research offers tailored laboratory services to propel preclinical programs forward, from early-stage research to IND-enabling studies. In addition to laboratory capabilities, the organization also provides advisory services that encompass all aspects of drug development, including clinical phases. Specializing in programs that require strategic insight, operational agility, and scientific depth, Cadena Research is a trusted partner for startups, academic innovators, biotechnology firms, and large pharmaceutical companies globally, seeking to thrive in the complex landscape of radiopharmaceutical development.

For more details, visit Cadena Research and connect with them on LinkedIn.

About CPDC

As a not-for-profit organization, CPDC is dedicated to advancing nuclear medicine across Canada and beyond. Through strategic investments and expert guidance, CPDC has succeeded in enhancing the availability of radiopharmaceuticals. Over the past 17 years, CPDC has established four Canadian commercial entities that continue to meet the needs of both patients and physicians in the radiopharmaceutical space. To learn more about their endeavors, explore CPDC and follow them on LinkedIn.